Moses Makunje
Direttore Finanziario/CFO presso NUVATION BIO INC.
Patrimonio netto: 27 803 $ in data 30/04/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| David Hung | M | 66 | 6 anni | |
| Kim Blickenstaff | M | 71 | 5 anni | |
| Kathryn Falberg | F | 63 | 4 anni | |
| Robert D. Mashal | M | - | - | |
| Tony Vernon | M | 68 | 5 anni | |
| Robert Bazemore | M | 56 | 4 anni | |
| Jonathan Lim | M | 52 |
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | 5 anni |
| Kerry Wentworth | F | 51 | 2 anni | |
| Daniel Welch | M | 66 | 4 anni | |
| Richard Scheller | M | 70 |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | 5 anni |
| Gary Hattersley | M | 57 | 5 anni | |
| Stacy Markel | F | 59 | 5 anni | |
| David Hanley | M | 54 | 3 anni | |
| Dong Fang Liu | M | 54 | 2 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Oleg Nodelman | M | 47 | 2 anni | |
| Jennifer Fox | F | 53 | 3 anni | |
| Lisa V. DeLuca | M | - | - | |
| Thomas S. Templeman | M | 64 | 2 anni | |
| Sergey Yurasov | M | 55 | 3 anni | |
| Michelle Doig | F | 50 | 2 anni | |
| Alex Colville | M | - |
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | 1 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 21 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Moses Makunje
- Contatti personali
